Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib

Andrew J Piper-Vallillo; Daniel B Costa; Marwa A Sabe; Aarti Asnani

doi:10.1016/j.jaccao.2020.01.003

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib

JACC CardioOncol. 2020 Mar 17;2(1):119-122. doi: 10.1016/j.jaccao.2020.01.003. eCollection 2020 Mar.

Authors

Andrew J Piper-Vallillo¹, Daniel B Costa¹, Marwa A Sabe², Aarti Asnani³

Affiliations

¹ Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
² Advanced Heart Failure and Mechanical Circulatory Support Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
³ Cardio-Oncology Program and CardioVascular Institute, Beth Israel Deaconess Medical Institute, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Keywords: ECG, electrocardiogram; EGFR, epidermal growth factor receptor; LVEF, left ventricular ejection fraction; NRG, neuregulin; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor; TTE, transthoracic echocardiography; cardiotoxicity; epidermal growth factor receptor; heart failure; lung cancer; osimertinib.

Publication types

Review